Cardiac resynchronization therapy and B-type natriuretic peptide in heart failure

Chinese Medical Journal

Volumn 122, Issue 6, 2009, Pages 608-609

  Huang, De Jia ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EDITORIAL; EXERCISE; FUNCTIONAL STATUS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HOSPITALIZATION; HUMAN; MITRAL VALVE REGURGITATION; MORTALITY; OUTCOME ASSESSMENT; PATIENT CODING; PLACEBO EFFECT; PREDICTION; PROGNOSIS; QUALITY OF LIFE; TREATMENT RESPONSE; BLOOD; HEART PACING; METHODOLOGY; NOTE;

CARDIAC PACING, ARTIFICIAL; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 67649792073     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.06.002     Document Type: Editorial

References (10)

1. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117: e350-e408
2. Bayes-Genis A, Pascual-Figal D, Fabregat J, Domingo M, Planas F, Casas T, et al. Serial NT-pro BNP monitoring and outcomes in outpatients with decompensation of heart failure. Int J Canrdiol 2007; 120: 338-343.
3. Ding LG, Hua W, Zhang S, Chu JM, Chen KP, Wang Y, et al. Decrease of plasma N-terminal pro B-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure. Chin Med J 2009; 122: 618-622.
4. McAlister FA, Ezekowitz J, Hooton N, Vandermeer B, Spooner C, Dryden DM, et al. Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction: a systemic review. JAMA 2007; 297: 2502-2514.
5. Piccini JP, Hernandez AF, Dai D, Thomas KL, Lewis WR, Yancy CW, et al. Use of cardiac resynchronization therapy in patients hospitalized with heart failure. Circulation 2008; 118: 926-933.
6. Lecoq G, Leclercq C, Leray E, Crocq C, Alonso C, de Place C, et al. Clinical and electrocardiographic predictors of a positive response to cardiac resynchronization therapy in advanced heart failure. Eur Heart J 2005; 26: 1094-1100.
7. Diaz-infante E, Mont L, Leal J, García-Bolao I, Fernández-Lozano I, Hernández-Madrid A, et al. Predictors of lack of response to resynchronization therapy. Am J Cardiol 2005; 95: 1436-1440.
8. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853.
9. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159.
10. Cleland J, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijanowski M, et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response. J Am Coll Cardiol 2008; 52: 438-445.